Quality of life in patients with Fabry disease: a systematic review of the literature

Abstract

Fabry disease (FD), caused by deficiency of the lysosomal enzyme α-galactosidase-A, is a progressive multisystem disease. The disease is X-linked with generally more severe manifestations in males, but can impact on quality of life (QoL) of both male and female patients. The purpose of this literature review is to analyse the currently available data concerning QoL measurement, specifically which questionnaires have been used to measure QoL, how patients with FD score compared to the general population, and the effects of enzyme replacement therapy (ERT) on QoL. Fifty-four articles were relevant for this literature review. Patients with FD had a lower QoL compared to the general population. No definite conclusions could be drawn from the studies on the effect of ERT on QoL; natural history data is scarce, changes observed were limited and the cohorts were of small size. We propose that a FD specific questionnaire be made to accurately assess QoL in patients with FD.Electronic supplementary materialThe online version of this article (doi:10.1186/s13023-015-0296-8) contains supplementary material, which is available to authorized users.

Fabry Liga: Klinikinis Atvejis Ir Literatūros Apžvalga

“…Remiantis 15 metų rezultatais, PFT efektyviai mažina akroparastezijas, inkstų ir širdies pažeidimo progresavimą [9]. 2015 m. olandų mokslininkai atliko sisteminę analizę, kurios metu vertino pacientų gyvenimo kokybę skiriant gydymą PFT [16]. Dauguma Fabry liga sergančių pacientų gyvena gerokai blogiau, palyginti su bendra populiacija.…”

Biomarkers in Lysosomal Storage Diseases

“…The progression of the disease eventually leads to progressive renal impairment, heart diseases, or cerebrovascular disease (stroke) [13,14]. …”

The neurological manifestations of Fabry disease. A review

“…Для оценки степени выраженности и про-грессирования болезни у взрослых пациентов применя-ются также соответствующие шкалы: Mainz Severity Score Index (MSSI) и Fabry Outcome Survey Mainz Severity Score Index (FOS-MSSI) [80], а также стандартные опросники качества жизни пациентов [81].…”